Genezen offers contract process development, GMP viral vector production, transduced cell manufacturing, and testing services.
Genezen has raised $18.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2023.
Genezen's investors include Ampersand Capital Partners.
Genezen is headquartered in Indianapolis, United States.
Genezen offers contract process development, GMP viral vector production, transduced cell manufacturing, and testing services.
Genezen is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Genezen — Funding & Investors." VCBacked, November 2, 2023, https://www.vcbacked.co/company/genezen. Accessed November 13, 2026.
VCBacked. (2023). Genezen — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/genezen
{{cite web |title=Genezen — Funding & Investors |url=https://www.vcbacked.co/company/genezen |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Genezen? Request a listing update